Patents Examined by Traviss C. McIntosh, III
  • Patent number: 10842806
    Abstract: Provided are methods for treating ocular inflammatory disorders, including macular edema, using an AMP kinase activator, e.g., 5-aminoimidazole-4-carboxamide-1-?-d-ribofuranoside (AICAR). The method reduces inflammation, thereby minimizing the loss of vision or visual function associated with these ocular disorders.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: November 24, 2020
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Demetrios G. Vavvas, Joan W. Miller, Lucia Sobrin, Jun Suzuki
  • Patent number: 10844379
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: November 24, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 10815266
    Abstract: A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: October 27, 2020
    Assignee: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • Patent number: 10815264
    Abstract: The present application relates to novel nucleoside derivatives of formula (I) as claimed in claim 1, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: October 27, 2020
    Assignee: Southern Research Institute
    Inventors: Cyril B. Dousson, David Dukhan, Jean-Laurent Paparin, Christophe C. Parsy
  • Patent number: 10806745
    Abstract: Compounds for treatment of a patient having a tumour that is metastatic and/or that reduces an organ function, wherein the compounds are of the general formula: wherein X is O, NH and S, wherein n is 0, 1 or 2, wherein R1 and R2 are H, methyl or ethyl, or together form a group CR3R4, and wherein R3 and R4 are H, methyl or ethyl.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: October 20, 2020
    Inventor: Nalan Utku
  • Patent number: 10808004
    Abstract: What claimed is a method of sweetening or enhancing sweetening effect of a composition that is administered orally to an individual by adding a specific triterpene glycoside obtained from Momordica grosvenorii (Siraitia grosvenori).
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: October 20, 2020
    Assignee: Analyticon Discovery GmbH
    Inventors: Karsten Siems, Grit Kluge, Sven Jakupovic, Gregor Hetterling, Fotini Tschirintzi
  • Patent number: 10808003
    Abstract: Provided are a newly developed tandem malonate-based amphipathic molecule, a method of preparing the same, and a method of extracting, solubilizing, stabilizing, crystallizing or analyzing a membrane protein using the same. In addition, the compound may be used to efficiently extract membrane proteins having various structures and characteristics from a cell membrane, compared to a conventional compound, to stably store the proteins in an aqueous solution for a long time, and may be used in functional and structural analysis thereof. The analysis of the structures and functions of the membrane proteins is one of the most attractive fields in current biology and chemistry, which are closely related to new drug development.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: October 20, 2020
    Assignee: Industry-University Cooperation Foundation Hanyang University Erica Campus
    Inventors: Pil Seok Chae, Hazrat Hussain
  • Patent number: 10806729
    Abstract: The present invention relates to a quinoline derivative of formula (I) or anyone of its pharmaceutically acceptable salt, or anyone of its metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient; and then terminating said treatment when: the viral load is low or undetectable; and/or the level of CD4+ cell count is maintained or restored.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: October 20, 2020
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Didier Scherrer, Aude Garcel, Noelie Campos, Jamal Tazi, Audrey Vautrin, Florence Mahuteau, Romain Najman, Pauline Fornarelli
  • Patent number: 10800804
    Abstract: Provided is a compound of the general formula (1), which is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human, as well as a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: October 13, 2020
    Inventors: Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • Patent number: 10793591
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: October 6, 2020
    Assignee: Janssen BioPharma, Inc.
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith
  • Patent number: 10793589
    Abstract: The present invention relates to a newly developed resorcinarene-based amphipathic compound, a method for producing the same, and a method for extracting, solubilizing, stabilizing, crystallizing, or analyzing a membrane protein by using the same. In addition, compared to a conventional compound, the compound can efficiently extract, from a cell membrane, membrane proteins having a greater variety of structures and characteristics, and can stably store such membrane proteins for a long time in an aqueous solution. Therefore, the compound can be used to analyze the functions and structures of such membrane proteins. Analysis of the structures and functions of membrane proteins, being closely related to the development of new drugs, is one of the fields of greatest interest in biology and chemistry today.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: October 6, 2020
    Assignee: Industry-University Cooperation Foundation Hanyang University Erica Campus
    Inventors: Pil Seok Chae, Hazrat Hussain
  • Patent number: 10786523
    Abstract: This invention relates to pharmaceutical formulations of gemcitabine-[phenyl-(benzoxy-L-alaninyl)]-phosphate, a monophosphate derivative of the well-known oncology drug gemcitabine. In particular, the invention relates to formulations which comprise a polar aprotic solvent, preferably dimethyl acetamide (DMA). Formulations comprising this solvent provide therapeutically effective treatments of gemcitabine-[phenyl-(benzoxy-L-alaninyl)]-phosphate. The invention also relates to methods of using said formulations and kits comprising said formulations.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: September 29, 2020
    Assignee: NuCana plc
    Inventors: Hugh Griffith, Gordon Kennovin
  • Patent number: 10781229
    Abstract: The present invention relates to a TRIS- or neopentyl glycol-based amphipathic compound, a method of preparing the same, and a method of extracting, solubilizing, stabilizing, or crystallizing a membrane protein using the same. By using the TRIS- or neopentyl glycol-based compound according to the present invention, a superior membrane protein solubilization effect is exhibited, a membrane protein can be stably stored for a long time in an aqueous solution, and the structural fluidity of the membrane protein can be excellently maintained. Accordingly, the TRIS- or neopentyl glycol-based compound can be utilized in analyzing functions and structures of membrane proteins. Membrane protein structure and function analysis is currently one of the most attractive fields of research in biology and chemistry. Since more than half of the new drugs under development target membrane proteins, the compound can be applied to membrane protein structure research closely related to drug discovery.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: September 22, 2020
    Assignee: Industry-University Cooperation Foundation Hanyang University Erica Campus
    Inventors: Pil Seok Chae, Aiman Sadaf
  • Patent number: 10781230
    Abstract: The present invention provides a novel nucleoside derivative or a salt thereof, a polynucleotide synthesis reagent, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. The nucleoside derivative or a salt thereof of the present invention is represented by the following chemical formula (1): where in the chemical formula (1), Su is an atomic group having a sugar skeleton at a nucleoside residue or an atomic group having a sugar phosphate skeleton at a nucleotide residue, and may or may not have a protecting group, L1 and L2 are each independently a straight-chain or branched, saturated or unsaturated hydrocarbon group having 2 to 10 carbon atoms, X1 and X2 are each independently an imino group (—NR1—), an ether group (—O—), or a thioether group (—S—), and the R1 is a hydrogen atom or a straight-chain or branched, saturated or unsaturated hydrocarbon group having 2 to 10 carbon atoms.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: September 22, 2020
    Assignees: NEC Solution Innovators, Ltd., NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY
    Inventors: Hirotaka Minagawa, Katsunori Horii, Jou Akitomi, Naoto Kaneko, Iwao Waga, Masayasu Kuwahara
  • Patent number: 10774102
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: September 15, 2020
    Assignee: Galecto Biotech AB
    Inventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • Patent number: 10774106
    Abstract: The present invention relates to compounds of the formula I: including any possible stereoisomers thereof, wherein R9 has the meaning as defined herein, or a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: September 15, 2020
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Ioannis Nicolaos Houpis, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
  • Patent number: 10765692
    Abstract: The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: September 8, 2020
    Assignee: Shire Viropharma Incorporated
    Inventor: John D. Peabody, III
  • Patent number: 10765690
    Abstract: Disclosed is a TLR4 agonist alone or in combination with an anti-cancer agent and pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said composition or combination, including uses in cancer.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: September 8, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Christopher W. Cluff, Hua-Xin Gao
  • Patent number: 10766916
    Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: September 8, 2020
    Assignee: GLYCOMIMETICS, INC.
    Inventors: John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
  • Patent number: 10759877
    Abstract: The presently disclosed subject matter provides nitric oxide-releasing polysaccharides and oligosaccharides, in particular, polyglucosamines, and their use in biomedical and pharmaceutical applications. More particularly, in some embodiments, the presently disclosed subject matter provides nitric oxide-releasing polysaccharides and oligosaccharides that release nitric oxide in a controlled and targeted manner, thereby prolonging the therapeutic effects of nitric oxide and improving the specificity of nitric oxide delivery to targeted cells and/or tissues.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: September 1, 2020
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Mark H. Schoenfisch, Yuan Lu